841 / 1983
Tra
Hou Z et al., J Cancer Res Clin Oncol. 2015 Jun;141(6):1063-71
6 RCTs, 2822 patients
Endpoint: 10-year efficacy of CDRT vs HDRT
- OS = no difference
- PCSS = no difference
- Better BFS : 34.0 vs. 24.7 % (p < 0.00001).
- Toxicity: HDRT significantly increased:
- late Grade 2+ GI tox (28.0 vs. 18.6 %, p < 0.0001)
- late G2+ GU toxicity (22.6 vs. 19.5 %, p = 0.04).